Чланци са овлашћеним јавним приступом - Eugeen VanmechelenСазнајте више
Није доступно нигде: 2
Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples
E Pérez-Ruiz, D Decrop, K Ven, L Tripodi, K Leirs, J Rosseels, ...
Analytica chimica acta 1015, 74-81, 2018
Овлашћења: Research Foundation (Flanders)
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
NG de San José, J Goossens, MR Al Shweiki, S Halbgebauer, P Oeckl, ...
Journal of psychiatric research 156, 390-397, 2022
Овлашћења: European Commission, Federal Ministry of Education and Research, Germany
Доступно негде: 83
The β-secretase BACE1 in Alzheimer’s disease
H Hampel, R Vassar, B De Strooper, J Hardy, M Willem, N Singh, J Zhou, ...
Biological psychiatry 89 (8), 745-756, 2021
Овлашћења: US National Institutes of Health, UK Medical Research Council, Parkinson's …
A practical guide to immunoassay method validation
U Andreasson, A Perret-Liaudet, LJC van Waalwijk van Doorn, ...
Frontiers in neurology 6, 179, 2015
Овлашћења: Research Foundation (Flanders), Swedish Research Council, Netherlands …
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people
G De Meyer, F Shapiro, H Vanderstichele, E Vanmechelen, ...
Archives of neurology 67 (8), 949-956, 2010
Овлашћења: US National Institutes of Health
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
NJ Ashton, TA Pascoal, TK Karikari, AL Benedet, J Lantero-Rodriguez, ...
Acta neuropathologica 141, 709-724, 2021
Овлашћења: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé …
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
S Hall, A Öhrfelt, R Constantinescu, U Andreasson, Y Surova, F Bostrom, ...
Archives of neurology 69 (11), 1445-1452, 2012
Овлашћења: Swedish Research Council
Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
O Hansson, H Zetterberg, E Vanmechelen, H Vanderstichele, ...
Neurobiology of aging 31 (3), 357-367, 2010
Овлашћења: Swedish Research Council
Biochemistry of Tau in Alzheimer’s disease and related neurological disorders
N Sergeant, A Bretteville, M Hamdane, ML Caillet-Boudin, P Grognet, ...
Expert review of proteomics 5 (2), 207-224, 2008
Овлашћења: National Institute of Health and Medical Research, France
Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update
M Del Campo, B Mollenhauer, A Bertolotto, S Engelborghs, H Hampel, ...
Biomarkers in medicine 6 (4), 419-430, 2012
Овлашћења: Research Foundation (Flanders)
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
M Milà-Alomà, NJ Ashton, M Shekari, G Salvadó, P Ortiz-Romero, ...
Nature medicine 28 (9), 1797-1801, 2022
Овлашћења: US National Institutes of Health, Banking Foundation "la Caixa", Academy of …
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
S Engelborghs, K De Vreese, T Van de Casteele, H Vanderstichele, ...
Neurobiology of aging 29 (8), 1143-1159, 2008
Овлашћења: Research Foundation (Flanders)
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ …
M Suárez‐Calvet, TK Karikari, NJ Ashton, J Lantero Rodriguez, ...
EMBO molecular medicine 12 (12), e12921, 2020
Овлашћења: Banking Foundation "la Caixa", Swedish Research Council for Environment …
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
S Janelidze, D Bali, NJ Ashton, NR Barthélemy, J Vanbrabant, E Stoops, ...
Brain 146 (4), 1592-1601, 2023
Овлашћења: US National Institutes of Health, Knut and Alice Wallenberg Foundation …
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
NJ Ashton, S Janelidze, N Mattsson-Carlgren, AP Binette, O Strandberg, ...
Nature medicine 28 (12), 2555-2562, 2022
Овлашћења: US National Institutes of Health, Knut and Alice Wallenberg Foundation …
Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology
NJ Ashton, WS Brum, G Di Molfetta, AL Benedet, B Arslan, E Jonaitis, ...
JAMA neurology 81 (3), 255-263, 2024
Овлашћења: US National Institutes of Health, Swedish Research Council, UK Medical …
Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes
MM Mielke, RD Frank, JL Dage, A Jeromin, NJ Ashton, K Blennow, ...
JAMA neurology 78 (9), 1108-1117, 2021
Овлашћења: US National Institutes of Health, Swedish Research Council, UK Medical …
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
A Vergallo, L Megret, S Lista, E Cavedo, H Zetterberg, K Blennow, ...
Alzheimer's & Dementia 15 (6), 764-775, 2019
Овлашћења: Research Foundation (Flanders), National Institute of Health and Medical …
Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years
J Hertze, L Minthon, H Zetterberg, E Vanmechelen, K Blennow, ...
Journal of Alzheimer's Disease 21 (4), 1119-1128, 2010
Овлашћења: Swedish Research Council
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
P Chatterjee, S Pedrini, NJ Ashton, M Tegg, K Goozee, AK Singh, ...
Alzheimer's & Dementia 18 (6), 1141-1154, 2022
Овлашћења: US National Institutes of Health, National Health and Medical Research …
Публикације и информације о финансирању аутоматски одређује рачунарски програм